Tianjin University of Traditional Chinese Medicine (China)
Inventor
Zhang, Boli
Zhang, Junhua
Song, Xinbo
Zhang, Han
Miao, Lin
Zhou, Kun
Ren, Ming
Liu, Erwei
Wang, Yuefei
Zheng, Wenke
Yang, Fengwen
Abstract
The present invention relates to a pharmaceutical composition for use preventing and curing respiratory diseases in winter. The composition comprises burdock seeds, blackberry lily, Platycodon grandiflorus, radix paeoniae rubra, Perilla frutescens, honeysuckle, fructus crataegi, Astragalus membranaceus, Reynoutria japonica, Glycyrrhiza uralensis, and non-essential fermented tea. The present invention also relates to a pharmaceutical preparation use of the pharmaceutical composition. The pharmaceutical composition can be used for nourishing Qi, moistening lungs, clearing throats, relieving sore throats and/or decontaminating, and can be used for preparing a pharmaceutical for treating and/or preventing pharyngitis.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Liu, Zhidong
Qi, Dongli
Peng, Hui
Pi, Jiaxin
Guo, Pan
Deng, Xiuping
Li, Jiawei
Abstract
The present application provides a compound dry powder inhalant, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, wherein based on a mass of the compound dry powder inhalant, L-leucine accounts for 0-50%, phosphate accounts for 15-35%, and a total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, and wherein a mass ratio of baicalin to ambroxol hydrochloride is 1:0.2 to 2. The compound dry powder inhalant has a Dv90≤5 μm. The drug combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage in lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and pulmonary fibrosis.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 11/00 - Drugs for disorders of the respiratory system
3.
COMPOUND DRY POWDER INHALER AND APPLICATION THEREOF
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Liu, Zhidong
Qi, Dongli
Peng, Hui
Pi, Jiaxin
Guo, Pan
Deng, Xiuping
Li, Jiawei
Abstract
A compound dry powder inhaler, comprising baicalin, ambroxol hydrochloride, L-leucine, and a phosphate, according to the mass of the compound dry powder inhaler, L-leucine accounting for 0-50%, the phosphate accounting for 15-35%, and the total mass of baicalin and ambroxol hydrochloride accounting for 15-85%, wherein the mass ratio of baicalin to ambroxol hydrochloride is 1:(0.2-2); the Dv90 of the compound dry powder inhaler is less than or equal to 5 μm. In the compound dry powder inhaler, the combination of baicalin and ambroxol hydrochloridecan effectively reduce the inflammation and oxidative damage of lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and fibrosis; pulmonary administration can prolong the half-life period of the drug in plasma and the residence time in the body, increase the bioavailability in the lung tissue, reduce the clearance rate of the drug in the lung tissue, and prolong the residence time of the drug in the lung.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Zhang, Boli
Zhang, Junhua
Liu, Qingquan
Yang, Fengwen
Huang, Ming
Guo, Yongming
Song, Xinbo
Zhang, Han
Wang, Yuefei
Chang, Yanxu
Liu, Erwei
Zheng, Wenke
Abstract
A traditional Chinese medicine composition for infectious disease recovery, containing the Chinese medicinal herbs: 2-4 parts of ginseng, 4-8 parts of Ophiopogon japonicus, 2-4 parts of Schisandra chinensis berry, 6-10 parts of Wolfiporia extensa Ginns, 6-10 parts of rhizoma pinelliae, 4-8 parts of Scrophularia ningpoensis, 4-6 parts of stir-fried Atractylodes, 4-8 parts of mandarin orange peel, 2-4 parts of Glycyrrhiza uralensis, 4-8 parts of Bupleurum scorzonerifolium, 2-4 parts of Actaea cimicifuga, 8-12 parts of Coix lacryma-jobi, 8-12 parts of Scutellaria baicalensis, 8-12 parts of Verbena officinalis, 12-18 parts of rhizoma phragmitis, and 1-3 parts of Lophatherum gracile. The present traditional Chinese medicine composition can be used in medicines for the prevention, treatment, or alleviation of the sequelae or complications of infectious diseases or for the promotion of the functional recovery of damaged tissues, organs or systems caused by infectious diseases.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Gao, Xiumei
Zhang, Boli
Liu, Erwei
Mao, Haoping
Yang, Wenzhi
Chen, Xiaopeng
Han, Lifeng
Zhang, Han
Tao, Rui
Chen, Lu
Abstract
A pharmaceutical composition for treating and/or preventing osteoporosis, the pharmaceutical composition comprising 2-8 parts by weight of Ligustri lucidi fructus, 2-8 parts by weight of Ecliptae herba, 1-5 parts by weight of Spatholobi caulis, and 1-5 parts by weight of Achyranthis bidentatae radix. The pharmaceutical composition can effectively prevent and treat osteoporosis, perimenopausal syndrome, constipation or obesity and reduce blood fat, and has a better effect than that of the Erzhi formula.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Liu, Zhidong
Qi, Dongli
Zhang, Bing
Li, Nan
Guo, Pan
Pi, Jiaxin
Deng, Xiuping
Li, Jiawei
Abstract
22], and dissolving in a first organic solvent to prepare a first solution; taking a lipid and distearoylphosphatidylethanolamine-polyethylene glycol-folic acid and dissolving in a second organic solvent to prepare a second solution: mixing and stirring the first solution and the second solution even to prepare an oil phase; and dripping the oil phase into the aqueous phase, and then heating to remove the organic solvent, and cooling to obtain the product. The present nano-structured lipid preparation has small and uniform particle size, strong tumor targeting, enhanced anti-tumor effects, and reduced renal toxicity.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Zhang, Boli
Zhang, Junhua
Song, Xinbo
Zhang, Han
Miao, Lin
Zhou, Kun
Ren, Ming
Liu, Erwei
Wang, Yuefei
Zheng, Wenke
Yang, Fengwen
Abstract
The present invention relates to a pharmaceutical composition for use preventing and curing respiratory diseases in winter. The composition comprises burdock seeds, blackberry lily, Platycodon grandiflorus, radix paeoniae rubra, Perilla frutescens, honeysuckle, fructus crataegi, Astragalus membranaceus, Reynoutria japonica, Glycyrrhiza uralensis, and non-essential fermented tea. The present invention also relates to a pharmaceutical preparation use of the pharmaceutical composition. The pharmaceutical composition can be used for nourishing Qi, moistening lungs, clearing throats, relieving sore throats and/or decontaminating, and can be used for preparing a pharmaceutical for treating and/or preventing pharyngitis.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Zhang, Boli
Liu, Qingquan
Gao, Xiumei
Zhang, Junhua
Song, Xinbo
Zhang, Lei
Cheng, Yiyu
Wang, Yi
Yang, Fengwen
Zheng, Wenke
Wang, Tao
Wang, Yuefei
Zhang, Han
Huang, Yuhong
Wang, Ping
Liu, Erwei
Liu, Dailin
Zhang, Jingze
Huang, Ming
Abstract
The present invention relates to a pharmaceutical composition for the treatment of coronavirus diseases, a preparation method therefor, and application thereof. The pharmaceutical composition contains a first Chinese herbal medicine extract and a second Chinese herbal medicine extract as active ingredients, the first Chinese medicinal extract being water or alcohol extracts of ephedra, bitter almond, raw gypsum, coix seed, atractylodes, patchouli, polygonum cuspidatum, verbena, reed root, lepidium seed, pummelo peel, and sweet wormwood, and the second Chinese herbal medicine extract being the water or alcohol extract of licorice. The pharmaceutical composition per ten grams contains not less than 2.3 mg of ephedrine hydrochloride and pseudoephedrine hydrochloride in total, not less than 42.7 mg of naringin, and not less than 7.7 mg of glycyrrhizic acid. The pharmaceutical composition of the present invention can be used for treatment of diseases caused by coronaviruses.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Wang, Shaoxia
Hu, Limin
Min, Jiang
Zhang, Yue
Guo, Hong
Gan, Guofeng
Abstract
An application of muscone in preparation of drugs for treating neuroimmune diseases The neuroimmune diseases refer to the neuroimmune diseases caused by microglia-mediated neurotoxic effects, including Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Gujarat disease.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Tianjin University of Traditional Chinese Medicine (China)
Inventor
Wang, Tao
Zhang, Yi
Liu, Erwei
Han, Lifeng
Ge, Dandan
Gao, Xiumei
Abstract
Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.
C07H 1/00 - Processes for the preparation of sugar derivatives
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
TIANJIN UNVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Gao, Xiumei
Abstract
Use of chemical ingredients in Cynomorium as phytoestrogen is provided by the present invention. Particularly, use of Cynomorium, extracts of Cynomorium, or at least one ingredient chosen from chrysophanol, emodin, catechin, (-)-epicatechin-3-O-gallate, naringenin-4'-O-glucopyranoside, and phlorizin, in manufacturing medicaments for treating and/or preventing diseases related to insufficient of estrogen secretion in mammal (for example, human), or use in manufacturing medicaments used as phytoestrogens is provided by the present invention. The extracts of Cynomorium, compositions containing extracts of Cynomorium or active ingredients thereof, and methods of treating and/or preventing diseases related to insufficient of estrogen secretion are also provided by the present invention. According to the present invention, Cynomorium, extracts of Cynomorium, active ingredients thereof can be used to treat and/or prevent menopausal syndrome, osteoporosis, degenerative osteoporosis, cardiovascular and cerebrovascular diseases and breast cancer.
TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Wang, Tao
Zhang, Yi
Liu, Erwei
Han, Lifeng
Ge, Dandan
Gao, Xiumei
Abstract
Foliamangiferosides having the general formula (I) are disclosed, wherein R is H or -OCH3. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.
C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
C07H 1/08 - SeparationPurification from natural products
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
patents
